This conference dives into the diagnosis, pathophysiology, and treatment of Long COVID and related post-acute infection syndromes (PAIS) including ME/CFS, post-Lyme, and post-viral conditions. Leading experts will tackle mechanisms ranging from viral persistence and autoimmunity to metabolic, neurological, and cardiovascular sequelae, with focus on biomarkers, cohort heterogeneity, and emerging diagnostics and therapeutics. It also explores epidemiology, demographics, machine learning approaches to symptom clustering, and the overlap with neurodegenerative illness. The program includes updates on ongoing clinical trials, animal model development, and strategies for future translational research. The targeted outcome is to catalyze collaborative interactions among researchers, clinicians, and patients from different backgrounds, fostering a proactive and accelerated approach to unraveling the complexities of Long COVID and other PAIS, and formulating effective strategies for diagnosis, treatment, and care.